IL270304B2 - Methods and preparations for the treatment of inflammatory disorders in the digestive system - Google Patents

Methods and preparations for the treatment of inflammatory disorders in the digestive system

Info

Publication number
IL270304B2
IL270304B2 IL270304A IL27030419A IL270304B2 IL 270304 B2 IL270304 B2 IL 270304B2 IL 270304 A IL270304 A IL 270304A IL 27030419 A IL27030419 A IL 27030419A IL 270304 B2 IL270304 B2 IL 270304B2
Authority
IL
Israel
Prior art keywords
seq
antibody
amino acid
acid sequence
composition
Prior art date
Application number
IL270304A
Other languages
English (en)
Hebrew (he)
Other versions
IL270304B1 (en
IL270304A (en
Original Assignee
Allakos Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allakos Inc filed Critical Allakos Inc
Publication of IL270304A publication Critical patent/IL270304A/en
Publication of IL270304B1 publication Critical patent/IL270304B1/en
Publication of IL270304B2 publication Critical patent/IL270304B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A61K39/001113—CD22, BL-CAM, siglec-2 or sialic acid- binding Ig-related lectin 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A61K39/225—Porcine transmissible gastroenteritis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06V—IMAGE OR VIDEO RECOGNITION OR UNDERSTANDING
    • G06V20/00—Scenes; Scene-specific elements
    • G06V20/60—Type of objects
    • G06V20/69—Microscopic objects, e.g. biological cells or cellular parts

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Multimedia (AREA)
  • Theoretical Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL270304A 2017-05-05 2018-05-04 Methods and preparations for the treatment of inflammatory disorders in the digestive system IL270304B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762502480P 2017-05-05 2017-05-05
US201762572337P 2017-10-13 2017-10-13
PCT/US2018/031231 WO2018204871A1 (en) 2017-05-05 2018-05-04 Methods and compositions for treating inflammatory gastrointestinal disorders

Publications (3)

Publication Number Publication Date
IL270304A IL270304A (en) 2019-12-31
IL270304B1 IL270304B1 (en) 2024-03-01
IL270304B2 true IL270304B2 (en) 2024-07-01

Family

ID=64016746

Family Applications (1)

Application Number Title Priority Date Filing Date
IL270304A IL270304B2 (en) 2017-05-05 2018-05-04 Methods and preparations for the treatment of inflammatory disorders in the digestive system

Country Status (13)

Country Link
US (1) US20200270344A1 (enExample)
EP (1) EP3618872A4 (enExample)
JP (2) JP7346304B2 (enExample)
KR (1) KR20200015511A (enExample)
CN (1) CN111246880A (enExample)
AU (1) AU2018263937A1 (enExample)
BR (1) BR112019022957A2 (enExample)
CA (1) CA3062430A1 (enExample)
IL (1) IL270304B2 (enExample)
MX (1) MX2019013136A (enExample)
SG (2) SG10202112259VA (enExample)
WO (1) WO2018204871A1 (enExample)
ZA (1) ZA201907372B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
HK1254432A1 (zh) 2015-06-17 2019-07-19 Allakos Inc. 用於治疗纤维性疾病的方法和组合物
BR112019022912A2 (pt) 2017-05-05 2020-05-26 Allakos Inc. Métodos e composições para tratar doenças oculares alérgicas
CA3087063A1 (en) 2017-12-29 2019-07-04 Cornell University Gene therapy for eosinophilic disorders
BR112021015009A2 (pt) * 2019-02-15 2021-10-05 Allakos Inc. Métodos e composições para o tratamento da gastrite mastocística, esofagite mastocística, enterite mastocística, duodenite mastocística e/ou gastroenterite mastocística
MX2022001403A (es) * 2019-08-02 2022-03-25 Allakos Inc Metodos de administracion de anticuerpos anti-siglec-8 y corticosteroides.
WO2021081411A1 (en) * 2019-10-24 2021-04-29 Allakos Inc. Methods and compositions for treating irritable bowel syndrome and functional dyspepsia
AU2021365008A1 (en) * 2020-10-22 2023-06-08 Allakos Inc. Anti-siglec-8 antibody formulations
EP4469601A1 (en) * 2022-01-24 2024-12-04 Children's Hospital Medical Center Methods of treating eosinophilic colitis
US20240225536A9 (en) * 2022-10-21 2024-07-11 Case Western Reserve University Radiomics signatures for pathologic characterization of strictures on mr and ct enterography
IL323497A (en) * 2023-03-27 2025-11-01 Regeneron Pharma Methods for treating eosinophilic gastroenteritis by administering an IL-4R antagonist
CN117187180B (zh) * 2023-11-03 2024-01-26 四川大学 一种Th17细胞及其培养方法和应用及其诱导液

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008145142A1 (en) * 2007-05-31 2008-12-04 Genmab A/S Stable igg4 antibodies
WO2015089117A1 (en) * 2013-12-09 2015-06-18 Allakos Inc. Anti-siglec-8 antibodies and methods of use thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7745421B2 (en) * 2004-05-25 2010-06-29 The Johns Hopkins University Methods and compositions for treating diseases and disorders associated with Siglec-8 expressing cells
CA2745439C (en) * 2008-12-03 2019-10-15 Genmab A/S Antibody variants having modifications in the constant region
EP2465873A1 (en) * 2010-12-16 2012-06-20 Deutsches Rheuma-Forschungszentrum Berlin Eosinophils as a therapeutic target
AU2012272559C1 (en) * 2011-06-23 2017-04-20 Children's Hospital Medical Center Molecular diagnostic panel of eosinophilic gastrointestinal disorders
US9260756B2 (en) * 2012-02-24 2016-02-16 Children's Hospital Medical Center Esophageal microRNA expression profiles in eosinophilic esophagitis
TWI634900B (zh) * 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
JP6825909B2 (ja) * 2014-02-28 2021-02-03 アラコス インコーポレイテッド シグレック−８関連疾患を処置するための方法および組成物
HK1254432A1 (zh) * 2015-06-17 2019-07-19 Allakos Inc. 用於治疗纤维性疾病的方法和组合物
US10604577B2 (en) * 2015-10-22 2020-03-31 Allakos Inc. Methods and compositions for treating systemic mastocytosis
BR112019022912A2 (pt) * 2017-05-05 2020-05-26 Allakos Inc. Métodos e composições para tratar doenças oculares alérgicas
GB201820174D0 (en) * 2018-12-11 2019-01-23 Nordic Semiconductor Asa Radio communication
BR112021015009A2 (pt) * 2019-02-15 2021-10-05 Allakos Inc. Métodos e composições para o tratamento da gastrite mastocística, esofagite mastocística, enterite mastocística, duodenite mastocística e/ou gastroenterite mastocística
JP2022535400A (ja) * 2019-06-07 2022-08-08 エピセリオン サイエンス バイオテック，エセ．エレ． 好酸球性消化管疾患の処置のためのイルソグラジン
MX2022001403A (es) * 2019-08-02 2022-03-25 Allakos Inc Metodos de administracion de anticuerpos anti-siglec-8 y corticosteroides.
WO2021081411A1 (en) * 2019-10-24 2021-04-29 Allakos Inc. Methods and compositions for treating irritable bowel syndrome and functional dyspepsia
JP2023511279A (ja) * 2020-01-13 2023-03-17 フルーエント バイオサイエンシーズ インコーポレイテッド 単一細胞シーケンシング
AU2021365008A1 (en) * 2020-10-22 2023-06-08 Allakos Inc. Anti-siglec-8 antibody formulations
US20240254441A1 (en) * 2021-06-04 2024-08-01 Kirin Holdings Kabushiki Kaisha Cell composition, method for producing cell composition, and pharmaceutical composition containing cell composition
KR20250007535A (ko) * 2022-04-22 2025-01-14 인히브릭스 바이오사이언스, 인크. Siglec-8 결합 단백질 및 그 용도

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008145142A1 (en) * 2007-05-31 2008-12-04 Genmab A/S Stable igg4 antibodies
WO2015089117A1 (en) * 2013-12-09 2015-06-18 Allakos Inc. Anti-siglec-8 antibodies and methods of use thereof

Also Published As

Publication number Publication date
IL270304B1 (en) 2024-03-01
AU2018263937A1 (en) 2019-12-05
IL270304A (en) 2019-12-31
JP7346304B2 (ja) 2023-09-19
CN111246880A (zh) 2020-06-05
US20200270344A1 (en) 2020-08-27
CA3062430A1 (en) 2018-11-08
KR20200015511A (ko) 2020-02-12
SG10202112259VA (en) 2021-12-30
ZA201907372B (en) 2024-04-24
SG11201910206QA (en) 2019-11-28
JP2020518645A (ja) 2020-06-25
EP3618872A1 (en) 2020-03-11
BR112019022957A2 (pt) 2020-05-19
MX2019013136A (es) 2020-07-14
WO2018204871A1 (en) 2018-11-08
EP3618872A4 (en) 2021-06-30
JP2023099232A (ja) 2023-07-11

Similar Documents

Publication Publication Date Title
US20200270344A1 (en) Methods and compositions for treating inflammatory gastrointestinal disorders
US20230331854A1 (en) Methods and compositions for treating systemic mastocytosis
US20220135673A1 (en) Methods and compositions for treating mast cell gastritis, mast cell esophagitis, mast cell enteritis, mast cell duodenitis, and/or mast cell gastroenteritis
US20220257758A1 (en) Methods of administering anti-siglec-8 antibodies and corticosteroids
US20190338027A1 (en) Methods and compositions for treating chronic obstructive pulmonary disorder
AU2021365008A1 (en) Anti-siglec-8 antibody formulations
AU2019262167A1 (en) Methods and compositions for treating chronic urticaria
US20220380460A1 (en) Methods and compositions for treating irritable bowel syndrome and functional dyspepsia
EA046789B1 (ru) Способы и композиции для лечения воспалительных расстройств желудочно-кишечного тракта